Author

Jillian Greenberg

Memorial Sloan Kettering Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Approach:genetic perturbation / CRISPR· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Elisa de StanchinaiD· 2 shared Gnana Prakasam KrishnamoorthyiD· 2 shared James A. FaginiD· 2 shared Jeffrey A. KnaufiD· 2 shared Laura BoucaiiD· 2 shared Richard P. KocheiD· 2 shared Soo-Yeon Im· 2 shared Tianyue QiniD· 2 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Elisa de StanchinaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Loss of tumor cell MHC Class II drives insensitivity of BRAF-mutant anaplastic thyroid cancers to MAPK inhibitors

Vera Tiedje, Jillian Greenberg, Tianyue Qin, Soo-Yeon Im, Gnana Prakasam Krishnamoorthy, Laura Boucai, Bin Xu, Jena D. French, Eric Jeffrey Sherman, Alan Loh Ho, Elisa de Stanchina, Nicholas D. Socci, Jian Jun Jin, Ronald A. Ghossein, Jeffrey A. Knauf, , James A. Fagin

This study shows that loss of MHC Class II in BRAF-mutant anaplastic thyroid cancers leads to resistance to MAPK inhibitors by reducing CD4+ T-cell activation.

Journal of Clinical Investigation · Aug 19, 2025Peer-reviewedCancer Biology

Targetable Treatment Resistance in Thyroid Cancer with Clonal Hematopoiesis

Vera Tiedje, Pablo Sánchez Vela, Julie L. Yang, Brian R. Untch, Laura Boucai, Aaron James Stonestrom, Alberto Bueno Costa, Sebastià Franch‐Expósito, Avi Srivastava, Marina Kerpelev, Jillian Greenberg, Mathew Wereski, Amanda R. Kulick, Kevin Chen, Tianyue Qin, , Ross L. Levine

This study identifies TET2-mutant clonal hematopoiesis in thyroid cancer microenvironments and shows that TGFβ signaling from these macrophages mediates resistance to BRAF/MEK inhibition, with TGFβ inhibition restoring sensitivity.

bioRxiv · Oct 10, 2024 · PreprintCancer Biology